The TrialNet study of the anti-inflammatory drug Canakinumab began last fall. Ultimately, the study will include 66 newly diagnosed diabetes patients aged 6 to 45.
For this study’s protocol—overseen by an Institutional Review Board—newly diagnosed patients receive monthly subcutaneous injections the first year, quarterly checkups the second year, and twice-yearly visits the final two years.
Two-thirds of participants will receive Canakinumab; one-third will receive a placebo. If successful, the drug will extend the “honeymoon” phase during which the pancreas continues functioning.
The University of Minnesota is also participating in other studies trying to alter the immune course of new onset diabetes. For more information, visit www.diabetestrialnet.org or email Toni Moran, M.D., moran001@umn.edu.
Read more about TrialNet.
